{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:38Z","timestamp":1786650098070,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Von Hippel-Lindau disease (VHL) is a major heritable renal cell cancer (RCC) syndrome. 24-45% of VHL patients have a cumulative risk to develop RCC. The management of VHL has changed significantly as clinicians have learned how to best balance the risk of cancer dissemination while minimizing renal morbidity. Despite the improving management of this disease, there are no evidence-based guidelines of the treatment of localized and advanced RCC in VHL. Here, we describe a 39-year-old patient with VHL disease who developed metastatic RCC and received sunitinib with complete remission.<\/jats:p>","DOI":"10.4103\/0973-1482.162120","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:48:49Z","timestamp":1455842929000},"page":"920-922","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease"],"prefix":"10.4103","volume":"11","author":[{"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[{"name":"Kidney Cancer Research Bureau, Moscow, Russian Federation, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","first-page":"1","article-title":"Renal cell carcinoma in the Russian federation in 2008","volume":"1","author":"Tsimafeyeu","year":"2010","journal-title":"Malign Tumours"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMp030061","article-title":"The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer","volume":"349","author":"George","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1074\/jbc.M511621200","article-title":"Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility","volume":"281","author":"Hsu","year":"2006","journal-title":"J Biol Chem"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000370118","article-title":"Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma","volume":"88","author":"Tsimafeyeu","year":"2015","journal-title":"Oncology"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s10637-013-0017-x","article-title":"OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model","volume":"31","author":"Tsimafeyeu","year":"2013","journal-title":"Invest New Drugs"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.12107","article-title":"Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-\u03b1","volume":"112","author":"Tsimafeyeu","year":"2013","journal-title":"BJU Int"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10689-014-9771-y","article-title":"First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: Clinical outcome and patterns of radiological response","volume":"14","author":"Roma","year":"2015","journal-title":"Fam Cancer"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4143\/crt.2013.45.4.349","article-title":"Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease","volume":"45","author":"Kim","year":"2013","journal-title":"Cancer Res Treat"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4103\/0973-1482.77084","article-title":"Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease","volume":"6","author":"Tsimafeyeu","year":"2010","journal-title":"J Cancer Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:02:19Z","timestamp":1786647739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.162120","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}